암환자의 치료범위를 벗어난 INR 원인 분석
Causes for Non-therapeutic INRs in Cancer Patients: Single Center Analysis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Although thromboembolism is common and one of the major causes of mortality in cancer patients, maintaining therapeutic anticoagulation effect with warfarin is challenging. This study aimed to determine the prevalence and the causes of non-therapeutic INR (International Normalized Ratio) in cancer patients. Methods: Medical and pharmacy records for cancer patients managed by the pharmacist-run anticoagulation service (ACS) between May, 2010 and April, 2011 at Seoul National University Hospital were retrospectively reviewed. The causes of non-therapeutic INR were identified and compared with the results from a former study with mechanical heart valve patients. Results: A total of 335 cancer patients and 6,737 patient-visits were analyzed producing 68% (n=4,590) of non-therapeutic INR readings. Eightyfive percent of the non-therapeutic INR readings were categorized as sub-therapeutic. Frequent causes linked to non-therapeutic INR included inadequate dosage adjustment (21.8%), changes in health status (11.8%), dietary changes (8.1%), and drug interactions (4.2%). More than half of the non-therapeutic INR values had no known etiology. As causes for non-therapeutic INR, changes in health status (p<0.0001), adverse reactions (p<0.0001), and dietary changes (p=0.017) were statistically more frequent in cancer patients than in patients with mechanical heart valves. Furthermore, exposure to sub-therapeutic INR were more prevalent in cancer patients than in patients with mechanical heart valve (p<0.0001). Conclusions: This study shows that there is a tendency to keep the level of INR low and that health status change, dietary change, and drug interactions are found to be frequent causes for non-therapeutic INR in cancer patients.
Abstract
Background: Although thromboembolism is common and one of the major causes of mortality in cancer patients, maintaining therapeutic anticoagulation effect with warfarin is challenging. This study aimed to determine the prevalence and the causes of non-therapeutic INR (International Normalized Ratio) in cancer patients. Methods: Medical and pharmacy records for cancer patients managed by the pharmacist-run anticoagulation service (ACS) between May, 2010 and April, 2011 at Seoul National University Hospital were retrospectively reviewed. The causes of non-therapeutic INR were identified and compared with the results from a former study with mechanical heart valve patients. Results: A total of 335 cancer patients and 6,737 patient-visits were analyzed producing 68% (n=4,590) of non-therapeutic INR readings. Eightyfive percent of the non-therapeutic INR readings were categorized as sub-therapeutic. Frequent causes linked to non-therapeutic INR included inadequate dosage adjustment (21.8%), changes in health status (11.8%), dietary changes (8.1%), and drug interactions (4.2%). More than half of the non-therapeutic INR values had no known etiology. As causes for non-therapeutic INR, changes in health status (p<0.0001), adverse reactions (p<0.0001), and dietary changes (p=0.017) were statistically more frequent in cancer patients than in patients with mechanical heart valves. Furthermore, exposure to sub-therapeutic INR were more prevalent in cancer patients than in patients with mechanical heart valve (p<0.0001). Conclusions: This study shows that there is a tendency to keep the level of INR low and that health status change, dietary change, and drug interactions are found to be frequent causes for non-therapeutic INR in cancer patients.
참고문헌 (27)
- Prandoni P, "thrombosis and heparin-induced thrombocytopenia", Thromb Res, 120(2), pp.137~140 (2007)
- Lee AY, "Venous thromboembolism and cancer : risks and outcomes", Circulation, 107(23), pp.117~121 (2003)
- Lyman GH, "American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer", J Clin Oncol, 25(34), pp.1~16 (2007)
- Blom JW, "Malignancies, prothrombotic mutations and the risk of venous thrombosis", JAMA, 293(6), pp.715~722 (2005)
- Semarad TJ, "Epidemiology of venous thromboembolism in 9489 with malignant glioma", J Neurosurg, 106(4), pp.601~608 (2007)
- Hutten BA, "Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio : a retrospective analysis", J Clin Oncol, 18(17), pp.3078~3083 (2000)
- Akl EA, "Thromboprophylaxis for patients with cancer and central venous catheters : a systematic review and a meta-analysis", Cancer, 112(11), pp.2483~2492 (2008)
- Carrier M, "Prophylactic and therapeutic anticoagulation for thrombosis-major issues in oncology", Nature Clinical Practice, 6(2), pp.74~84 (2009)
- Geerts WH, "American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 133(6), pp.381~453 (2008)
- "National cancer comprehensive network clinical practice guidelines in oncology: Venous Thromboembolic Disease V.1.2009" (2009)[URL]
- Adamson D. J. A, "Occult malignancy is associated with venous thrombosis unresponsive to adequate anticoagulation", Br J Clin Pract, 47(4), pp.190~191 (1993)
- Lars J, "Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients : A review of current guidelines", Cancer Treatment Reviews, 35(8), pp.754~764 (2009)
- 이병구, "인공심장판막 치환환자의 치료범위를 벗어난 INR 원인분석", The Korean Journal of Thoracic and Cardiovascular Surgery, 38(11), pp.746~760 (2005), 대한흉부외과학회
- Nutescu E, "Drug and dietary interactions of warfarin and novel oral anticoagulants : and update", J Thromb Thrombolysis, 31(3), pp.326~343 (2011)
- Lacy CF, "Lexi-Comp’s Drug Information Handbook" (2008), Lexi-Comp Inc
- Lee AY, "Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer", N Engl J Med, 349, pp.146~153 (2003)
- Jones KL, "Clinical outcomes of a pharmacist-managed anticoagulation service for breast cancer patients", Oncol Pharm Pract, 18(1), pp.122~127 (2012)
- Rose AJ, "Effectiveness of warfarin among patients with cancer", J Gen Intern Med, 22(7), pp.997~1002 (2007)
- 곽혜선, "인공심장판막치환환자의 응급센터 내원시 warfarin에 의한 합병증에 관한 연구", 한국임상약학회지, 17(2), pp.70~75 (2007), 한국임상약학회
- Prandoni P, "Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and thrombosis", Blood, 100(10), pp.3484~3488 (2002)
- Grogan KM, "Examining differences in weekly warfarin dose in patients with and without cancer", Ther Drug Monit, 29(5), pp.638~643 (2007)
- Camidge R, "Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer", J Clin Oncol, 23(21), pp.4719~4725 (2005)
- Davis DA, "Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-fluorouracil therapy", Pharmacotherapy, 25(3), pp.442~447 (2005)
- Pangilinan JM, "Use of warfarin in the patient with cancer", J support Oncol, 5(3), pp.131~136 (2007)
- "Warfarin-indications, risks and drug interactions", Aust Fam Physician, 39(7), pp.476~479 (2010)
- Demirkan K, "Response to warfarin and other oral anticoagulants : effects of disease states", South Med J, 93(5), pp.448~454 (2000)
- Nutescu EA, "herbs and other dietary supplements", Expert Opin Drug Saf, 5(3), pp.433~451 (2006)